Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gamma-hydroxybutyrate
- Development stage
- Unknown
- Lead developer
- Psychiatrische Universitätsklinik Zürich
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Gamma-hydroxybutyrate (GHB) is a naturally occurring neurotransmitter and a small molecule central nervous system depressant being investigated by the Psychiatric University Hospital, Zurich, for the prevention of post-traumatic stress disorder (PTSD). In the TRAUMA-PRO clinical trial, GHB is administered as a post-exposure prophylaxis to healthy volunteers following an experimental trauma film to enhance slow-wave sleep (deep sleep). The therapeutic rationale is that boosting deep sleep shortly after a traumatic event facilitates the healthy consolidation of memories, thereby reducing the frequency and intensity of subsequent intrusive memories, which are a hallmark of PTSD. GHB acts primarily as a high-affinity agonist at the GHB receptor and a weak agonist at the gamma-aminobutyric acid type B (GABA-B) receptor.
- Brand names
- XyremXywav
- Other names
- GHBsodium oxybate4-hydroxybutanoic acid
02
Targets
GABRR (GABA-A receptor subunit rho)GABA-B (Gamma-aminobutyric acid receptor type B)
Beyond the preview
Go deeper on gamma-hydroxybutyrate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gamma-hydroxybutyrate.